Biomarkers in Parkinson’s disease: a funder’s perspective

Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease

(2010) William T. Hu et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum

(2010) Ozioma C. Okonkwo   ARCHIVES OF NEUROLOGY

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)

(2010) D. F. Wong et al.   JOURNAL OF NUCLEAR MEDICINE

In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133

(2010) N. Okamura et al.   JOURNAL OF NUCLEAR MEDICINE

Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly

(2010) Daniela Berg et al.   MOVEMENT DISORDERS

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

(2010) Harald Hampel et al.   NATURE REVIEWS DRUG DISCOVERY

Inner Retinal Layer Thinning in Parkinson Disease

(2009) Mohammedyusuf E. Hajee   ARCHIVES OF OPHTHALMOLOGY

Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration

(2009) Elisabeth Andreadou et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

The role of DAT-SPECT in movement disorders

(2009) G Kagi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

(2009) Sarah J Tabrizi et al.   LANCET NEUROLOGY

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

(2009) Richard J. Perrin et al.   NATURE

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

(2009) D. E. Vaillancourt et al.   NEUROLOGY

Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients

(2009) Yoshiro Saito et al.   NEUROSCIENCE LETTERS

Metabolomic profiling to develop blood biomarkers for Parkinson's disease

(2008) M. Bogdanov et al.   BRAIN

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

(2008) Brit Mollenhauer et al.   EXPERIMENTAL NEUROLOGY

Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling

(2008) Ferdousi Chowdhury et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients

(2008) M Hirotani et al.   Multiple Sclerosis Journal

MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE

(2008) L. H. Wang et al.   NEUROLOGY

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

(2008) Annika Öhrfelt et al.   NEUROSCIENCE LETTERS

A more efficient enzyme-linked immunosorbent assay for measurement of α-synuclein in cerebrospinal fluid

(2007) Wieneke J.A. van Geel et al.   JOURNAL OF NEUROSCIENCE METHODS